134 related articles for article (PubMed ID: 34869026)
1. Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300.
Marvaso G; Vischioni B; Pepa M; Zaffaroni M; Volpe S; Patti F; Bellerba F; Gandini S; Comi S; Corrao G; Zerini D; Augugliaro M; Fodor C; Russo S; Molinelli S; Ciocca M; Ricotti R; Valvo F; Giandini T; Avuzzi B; Valdagni R; De Cobelli O; Cattani F; Orlandi E; Jereczek-Fossa BA; Orecchia R
Front Oncol; 2021; 11():778729. PubMed ID: 34869026
[TBL] [Abstract][Full Text] [Related]
2. Phase II prospective trial "Give Me Five" short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218).
Marvaso G; Gugliandolo SG; Bellerba F; Gandini S; Corrao G; Volpe S; Rojas DP; Riva G; Zerini D; Pepa M; Fodor CI; La Rocca E; Pricolo P; Alessi S; Petralia G; Mistretta FA; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2020 Jul; 37(8):74. PubMed ID: 32725443
[TBL] [Abstract][Full Text] [Related]
3. Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients.
Marvaso G; Jereczek-Fossa BA; Vischioni B; Ciardo D; Giandini T; Hasegawa A; Cattani F; Carrara M; Ciocca M; Bedini N; Villa S; Morlino S; Russo S; Zerini D; Colangione SP; Panaino CMV; Fodor C; Santoro L; Pignoli E; Valvo F; Valdagni R; De Cobelli O; Orecchia R
Tumori; 2017 May; 103(3):314-318. PubMed ID: 28009421
[TBL] [Abstract][Full Text] [Related]
4. Mixed-beam approach for high-risk prostate cancer: Carbon-ion boost followed by photon intensity-modulated radiotherapy. Dosimetric and geometric evaluations (AIRC IG-14300).
Gugliandolo SG; Marvaso G; Comi S; Pepa M; Romanò C; Zerini D; Augugliaro M; Russo S; Vischioni B; Valvo F; Giandini T; Avuzzi B; Valdagni R; Ciardo D; De Cobelli O; Jereczek-Fossa BA; Cattani F; Orecchia R
Phys Med; 2020 Aug; 76():327-336. PubMed ID: 32750548
[TBL] [Abstract][Full Text] [Related]
5. Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE".
Marvaso G; Corrao G; Repetti I; Lorubbio C; Bellerba F; Zaffaroni M; Vincini MG; Zerini D; Alessi S; Luzzago S; Mistretta FA; Fodor C; Cambria R; Cattani F; Ceci F; Musi G; De Cobelli O; Zilli T; Gandini S; Orecchia R; Petralia G; Jereczek-Fossa BA
World J Urol; 2024 Mar; 42(1):169. PubMed ID: 38492078
[TBL] [Abstract][Full Text] [Related]
6. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
[TBL] [Abstract][Full Text] [Related]
7. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial.
Murthy V; Maitre P; Bhatia J; Kannan S; Krishnatry R; Prakash G; Bakshi G; Pal M; Menon S; Mahantshetty U
Radiother Oncol; 2020 Apr; 145():71-80. PubMed ID: 31923712
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study.
Junius S; Haustermans K; Bussels B; Oyen R; Vanstraelen B; Depuydt T; Verstraete J; Joniau S; Van Poppel H
Radiat Oncol; 2007 Aug; 2():29. PubMed ID: 17686162
[TBL] [Abstract][Full Text] [Related]
9. Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer.
Zhang Y; Li P; Yu Q; Wu S; Chen X; Zhang Q; Fu S
Radiat Oncol; 2019 Jun; 14(1):94. PubMed ID: 31164172
[TBL] [Abstract][Full Text] [Related]
10. Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
Dutz A; Agolli L; Baumann M; Troost EGC; Krause M; Hölscher T; Löck S
Acta Oncol; 2019 Jun; 58(6):916-925. PubMed ID: 30882264
[No Abstract] [Full Text] [Related]
11. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
12. Helical tomotherapy for prostate cancer radiation therapy: An audit of early toxicity and quality of life.
Kunheri B; Lakshmi JS; Ravindran GC; Haridas ; Marwaha V
J Cancer Res Ther; 2021; 17(2):366-371. PubMed ID: 34121678
[TBL] [Abstract][Full Text] [Related]
13. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
14. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan.
Nihei K; Ogino T; Ishikura S; Kawashima M; Nishimura H; Arahira S; Onozawa M
Jpn J Clin Oncol; 2005 Dec; 35(12):745-52. PubMed ID: 16314345
[TBL] [Abstract][Full Text] [Related]
15. Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218.
Timon G; Ciardo D; Bazani A; Marvaso G; Riva G; Volpe S; Rojas DP; Renne G; Petralia G; Zerini D; Fodor C; Dicuonzo S; Maestri D; Pansini F; Cambria R; Cattani F; Golino F; Scroffi V; De Lorenzo D; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Br J Radiol; 2018 Sep; 91(1089):20160725. PubMed ID: 29750539
[TBL] [Abstract][Full Text] [Related]
16. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II Trial Evaluating Carbon Ion Radiotherapy for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma.
Kong L; Hu J; Guan X; Gao J; Lu R; Lu JJ
J Cancer; 2016; 7(7):774-83. PubMed ID: 27162535
[TBL] [Abstract][Full Text] [Related]
18. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.
Kupelian PA; Reddy CA; Klein EA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):988-93. PubMed ID: 11704322
[TBL] [Abstract][Full Text] [Related]
19. Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.
Habl G; Uhl M; Katayama S; Kessel KA; Hatiboglu G; Hadaschik B; Edler L; Tichy D; Ellerbrock M; Haberer T; Wolf MB; Schlemmer HP; Debus J; Herfarth K
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):435-443. PubMed ID: 27084659
[TBL] [Abstract][Full Text] [Related]
20. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
